Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Proteins and Peptides

Human Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL), Active Protein

Product Sizes
50 ug
£516.00
RPU54878-50UG
100 ug
£786.00
RPU54878-100UG
1 mg
£2803.00
RPU54878-1MG
About this Product
SKU:
RPU54878
Additional Names:
Apo-2 Ligand|Apo2-L|APO2L|CD253|TL2|TNFSF10|TRAIL|Tumor Necrosis Factor Ligand Superfamily Member 10
Application:
Detection/Quantitation, Tissue Culture
Buffer:
Liquid|PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
CE/IVD:
RUO
Extra Details:
Human Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL), Active Protein is a purified Prokaryotic Protein.
Formulation:
Liquid
Immunogen:
Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL)
Molecular Weight:
19kDa
Physical State:
Liquid
Purity:
>95%
Shipping Conditions:
Blue Ice
Storage Conditions:
-20[o]C Avoid freeze/thaw cycles.
Supplier:
Biomatik
Type:
Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
Catalog Protein.JPG
Protein TRAIL (TNF-Related Apoptosis-Inducing Ligand) is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. TRAIL induces apoptosis in transformed and tumor cells. This protein binds to several members of TNF receptor superfamily including TNFRSF10B/TRAILR2. Thus a binding ELISA assay was conducted to detect the interaction of TRAIL and TNFRSF10B. Briefly, recombinant human TRAIL were diluted serially in PBS, with 0.01%BSA (pH 7.4). Duplicate samples of 100uL were then transferred to TNFRSF10B-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-TRAIL pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50uL stop solution to the wells and read at 450nm immediately. The binding activity of TRAIL and TNFRSF10B was shown in Figure 1, and this effect was in a dose dependent manner.
Figure 3. SDS-PAGE
Figure 3. SDS-PAGE